Clinical Laserthermia Systems AB Class B (SE:CLS.B)
:CLS.B
Want to see SE:CLS.B full AI Analyst Report?
Top Page
Clinical Laserthermia Systems AB Class B
(CLS.B)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr3.50
▼(-48.45% Downside)
Action:Reiterated
Date:05/29/26
The score is held down primarily by weak financial performance (large losses, negative margins, and persistent cash burn) and a bearish technical trend (price below key moving averages with negative MACD). A low-debt balance sheet provides some flexibility, but valuation remains constrained by ongoing losses (negative P/E) and no stated dividend support.
Positive Factors
Recurring revenue / installed base
The firm's business model includes capital equipment sales plus recurring consumables, software and service revenue tied to installed systems. This installed-base dynamic supports durable repeat purchases and revenue visibility over time, improving long-term margin leverage if clinical adoption grows.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow forces dependence on external financing or reserves. Even with some improvement, ongoing burn limits runway for commercialization and R&D, risks dilution from equity raises and constrains sustainable investment in sales and regulatory initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue / installed base
The firm's business model includes capital equipment sales plus recurring consumables, software and service revenue tied to installed systems. This installed-base dynamic supports durable repeat purchases and revenue visibility over time, improving long-term margin leverage if clinical adoption grows.
Read all positive factors
Clinical Laserthermia Systems AB Class B (CLS.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr111.42M
Dividend YieldN/A
Average Volume (3M)333.29K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue Growth-29.16%
EPS Growth44.24%
CountrySE
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.67
Shares Outstanding31,163,593
10 Day Avg. Volume370,302
30 Day Avg. Volume333,294
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr37.70M
Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model
Company Description
Founded in 2006 and based in Lund, Sweden, Clinical Laserthermia Systems AB (publ) specializes in crafting therapeutic instruments for treating diseased tissues, marketed under their TRANBERG brand. A core offering is the TRANBERG thermal therapy ...
How the Company Makes Money
CLS generates revenue primarily by commercializing its laserthermia platform, which typically involves (1) sales of capital equipment (the laser/monitoring system installed at hospitals/clinics), (2) recurring sales of procedure-related consumable...
Clinical Laserthermia Systems AB Class B Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.49M | 18.78M | 8.27M | 6.27M | 2.25M |
| Gross Profit | -29.00M | 10.42M | 3.00M | -2.79M | -3.63M |
| EBITDA | -26.41M | -44.76M | -68.41M | -57.84M | -57.05M |
| Net Income | -41.61M | -47.62M | -79.79M | -70.66M | -63.62M |
Balance Sheet | |||||
| Total Assets | 76.49M | 78.56M | 57.73M | 49.51M | 66.74M |
| Cash, Cash Equivalents and Short-Term Investments | 21.55M | 22.51M | 15.33M | 10.59M | 31.17M |
| Total Debt | 0.00 | 224.00K | 454.00K | 30.68M | 273.50K |
| Total Liabilities | 10.00M | 12.88M | 14.20M | 41.64M | 45.55M |
| Stockholders Equity | 69.67M | 68.72M | 45.77M | 9.22M | 21.79M |
Cash Flow | |||||
| Free Cash Flow | -35.91M | -58.92M | -71.95M | -71.25M | -66.73M |
| Operating Cash Flow | -33.20M | -56.45M | -66.45M | -70.69M | -66.17M |
| Investing Cash Flow | -2.80M | -7.47M | -5.50M | -886.00K | -408.00K |
| Financing Cash Flow | 35.04M | 71.10M | 76.69M | 61.84M | 85.88M |
Clinical Laserthermia Systems AB Class B Technical Analysis
Negative
6.79
Price Trends
4.12
Negative
5.18
Negative
6.64
Negative
Market Momentum
-0.19
Negative
42.37
Neutral
58.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Negative. The current price of 6.79 is above the 20-day moving average (MA) of 3.70, above the 50-day MA of 4.12, and above the 200-day MA of 6.64, indicating a bearish trend. The MACD of -0.19 indicates Negative momentum. The RSI at 42.37 is Neutral, neither overbought nor oversold. The STOCH value of 58.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CLS.B.
Clinical Laserthermia Systems AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr126.49M | 33.30 | ― | ― | -12.51% | -59.88% | |
52 Neutral | kr197.15M | -1.73 | ― | ― | ― | 68.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr136.33M | -16.03 | ― | ― | 59.15% | 10.47% | |
43 Neutral | kr111.42M | -3.30 | -61.62% | ― | -29.16% | 44.24% | |
43 Neutral | kr34.10M | -0.89 | -60.56% | ― | 27.31% | 6.31% | |
42 Neutral | kr28.24M | -0.46 | -50.21% | ― | ― | -85.81% |
* Healthcare Sector Average
SE:CLS.B
Clinical Laserthermia Systems AB Class B
3.58
0.74
26.10%
SE:SPEC
SpectraCure AB
0.05
-0.20
-80.40%
SE:LXB
Luxbright AB
0.13
-0.54
-80.33%
SE:HEART
Scandinavian Real Heart AB
23.20
9.00
63.39%
SE:NOSA
Nosa Plugs AB
0.52
-0.26
-33.42%
SE:ARCOMA
Arcoma AB
8.84
-0.56
-5.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.